Evidence indicates that EZH2 is implicated in the development and progression of multiple cancers, including breast cancer, bladder cancer, endometrial cancer, and prostate cancer, with elevated EZH2 levels correlating with increased tumor aggressiveness.[60, 61, 62] Accordingly, EZH2 inhibitors hold considerable promise as potential cancer therapeutics. Here, EZH2 is linked to urinary bladder carcinoma.